drugset / Trial / NCT04222842

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

NCT04222842

Phase 1 Suspended 96 enrolled AnewPharma
NaSequentialOpen-labelTreatment

Summary

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With mCNV.

Timeline

Start
2019-12-18
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CM082 Unknown 25 mg Oral
Subject CM082 Unknown 50 mg Oral